The company creates Orthotopic Patient-Derived Xenograft (O-PDX) mouse models by surgically implanting human tumors in specialized immunodeficient mice, which are used to evaluate cancer therapies and gain knowledge about how each treatment works against specific cancers. Certis evaluates therapeutic response using MRI images, digital tumor volume measurements, and investigations of cellular structures, delivering reliable oncology intelligence to patients, oncologists, and drug innovators.